Prognosis of surgically resected clinical stage 1A non-smallcelllungcancers manifesting as a subsolid nodule on computed tomography including pure ground glass nodules. This is a protocol for a Cochrane Review (prognosis). The objectives are as follows: To quantify the risk of tumour relapse/recurrence after a surgical resection of stage 1A non-smallcelllungcancer (NSCLC) as manifested
Zenocutuzumab zbco (Bizengri) - non-smallcelllungcancer and pancreatic adenocarcinoma Drug Approval Package: BIZENGRI * Skip to main content * Skip to FDA Search * Skip to footer links An official website of the United States governmentHere's how you know The .gov means it's official.Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're
Ensartinib (Ensacove) - non-smallcelllungcancer Drug Approval Package: ENSACOVE * Skip to main content * Skip to FDA Search * Skip to footer links An official website of the United States governmentHere's how you know The .gov means it's official.Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site
Therapeutic vaccines for advanced non-smallcelllungcancer. New strategies in immunotherapy with specific antigens that trigger an anti-tumour immune response in people with lung cancer open the possibility of developing therapeutic vaccines aimed at boosting the adaptive immune response against cancer cells. To evaluate the effectiveness and safety of different types of therapeutic vaccines for people with advanced non-smallcelllungcancer. We searched CENTRAL, MEDLINE, Embase, Wanfang Data, and China Journal Net (CNKI) up to 22 August 2023. We included parallel-group, randomised controlled trials evaluating a therapeutic cancer vaccine, alone or in combination with other treatments, in adults (> 18 years) with advanced non-smallcelllungcancer (NSCLC), whatever the line of treatment. We